Verhey F R J
Neuropsychiatrie en Ouderenpsychiatrie verbonden aan het Academisch Ziekenhuis Maastricht en de Universiteit Maastricht.
Tijdschr Psychiatr. 2006;48(1):17-26.
So far no causal therapies are available for the treatment of Alzheimer's disease. However, four drugs, namely donepezil, rivastigmine, galantamine and memantine, have been licensed for treating the symptoms of the disease.
To systematically review the efficacy and side-effects of these drugs.
With the help of Pubmed, Medline and the Cochrane Library the literature was searched systematically.
Cholinesterase-inhibitors and memantine do have a beneficial effect on cognition and daily functioning. The effect, however, is limited and the cholinesterase-inhibitors in particular frequently have side-effects.
Treatment with the new anti-Alzheimer drugs demands a careful and realistic approach. The drugs should not be prescribed in isolation but the treatment needs to be embedded in the entire set of currently available psychosocial intervention techniques.
到目前为止,尚无用于治疗阿尔茨海默病的因果疗法。然而,四种药物,即多奈哌齐、卡巴拉汀、加兰他敏和美金刚,已被批准用于治疗该疾病的症状。
系统评价这些药物的疗效和副作用。
借助PubMed、Medline和Cochrane图书馆系统检索文献。
胆碱酯酶抑制剂和美金刚对认知和日常功能确实有有益作用。然而,这种作用是有限的,尤其是胆碱酯酶抑制剂经常有副作用。
使用新型抗阿尔茨海默病药物进行治疗需要谨慎且现实的方法。这些药物不应单独开具处方,而是需要将治疗纳入目前所有可用的心理社会干预技术中。